CHLOROPTIC
LOE ApproachingNDAOPHTHALMICSOLUTION/DROPS
Approved
Mar 1968
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CHLOROPTIC is an ophthalmic solution (eye drops) approved in 1968 as a small-molecule NDA by AbbVie. The generic name and mechanism of action are not publicly disclosed in available data. It is administered topically to the eye for unspecified ophthalmic indications.
LOE Approaching
Product approaching loss of exclusivity with minimal commercial team investment; roles likely focused on market defense and transition planning rather than growth.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
CHLOROPTIC presents minimal career opportunity; zero linked job openings and approaching LOE signal a declining investment in this brand. Pharma professionals should expect role consolidation, market defense focus, and limited advancement potential.
Brand ManagerField Sales
Worked on CHLOROPTIC at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.